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Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer death in the world. Many
risk factors have been identified in the development of colorectal cancer. It is necessary
to carry out activities related to risk factors in order to implement effective CRC early
diagnosis and screening programs and achieve positive outcomes. International screening
guidelines have been created and these are being implemented by individual countries
according to their own health policies. Colorectal cancer prevention and early training in
terms of disease identification, counseling against negative disease perceptions, and
changing false beliefs will reduce the fear of CRC and ensure the development of positive
health behaviors and acceptance of screening. Among recent developments in cancer
prevention, “cancer risk counseling” has become quite prominent. Individual-specific
colorectal cancer risk counseling programs are developed through the assessment of
individual risk factors by focusing on a genetic assessment and the development of a risk
management plan. This chapter will examine and define colorectal cancer prevention and
risk counseling strategies in relation with the relative literature.
Keywords: Colorectal cancer, prevention, cancer risk counseling, screening, clinical
guidelines
1. Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer death in the world. Colorectal
cancer is a significant public health problem in many countries considering its incidence,
mortality rate, and treatment costs [1]. Among all cancer deaths, mortality due to CRC ranks
second in the world and accounts for 9–10% of all cancers deaths [2–4]. Colorectal cancer is the
second most common cancer worldwide [5]. The incidence of CRC in North America and highly
industrialized areas such as northwestern Europe and Australia is high, but is low in less
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developed regions such as Asia, Africa, and South America [2, 5, 6]. Lifetime risk of develop‐
ing CRC varies between 2.4 and 6%. Risk factors possessed by individuals may increase this rate
[2, 3]. It is necessary to carry out activities related to risk factors in order to implement effec‐
tive CRC early diagnosis and screening programs and achieve positive outcomes. Moreover,
implementing cost-effective screening programs decreases costs and increases the effective‐
ness of CRC screening [7, 8]. Many people do not know the risk factors for CRC; it is reported
that those who do know them should be encouraged and supported by professionals to apply
safeguard measures and effective interventions.  More than half  of CRC incidents can be
prevented by implementing protection strategies in accordance with risk factors [9, 10]. However,
to achieve this, negative behaviors must be changed to positive, and individuals should be
directed toward early diagnosis in accordance with their risk conditions and monitored [11, 12].
In the realization of primary and secondary prevention strategies, bespoke colon cancer risk
counseling is important for reducing morbidity and mortality [11–13].
2. Colorectal cancer prevention and risk counseling
2.1. Colorectal cancer prevention
2.1.1. Colorectal cancer risk factors
Advancing age, familial and genetic factors, environmental factors, and lifestyle/behavioral
factors affect the development of CRC [2, 6–8]. Colorectal cancer risk factors are divided into
two groups, those that can be changed and those that cannot [1, 6, 10].
Nonchangeable risk factors: These factors cannot be taken under control by the individual.
These include age, sex, genetics (personal or family history of CRC), chronic colon diseases
such as ulcerative colitis, inflammatory bowel disease or Crohn’s disease, and a history of
adenomatous polyps [6, 8, 10, 13].
Changeable risk factors: These are behavioral factors that can be altered or managed to help
reduce the risk of CRC. It is reported that more than half of all cancers are linked to risky health
behaviors. Changeable factors include but are not limited to smoking, moderate-to-heavy
levels of alcohol consumption, being overweight and obesity, unbalanced diet, excessive
consumption of red meat and/or processed meat products, physical inactivity, and/or
sedentary lifestyle [3, 4, 6, 8–10, 13–19]. Risk factors and their relative risk for CRC are shown
in Table 1. Colorectal cancer risk with relative risk above 1 indicates high risk, and less than
1 indicates low risk [10].
2.1.2. Colorectal cancer prevention strategies
The aim is to prevent cancer, precancerous lesions, and reduce the incidence of cancer-related
morbidity and mortality and cancer spread, or at least diagnose it at earlier stages. Cancer
prevention research, and the reduction of cancer morbidity and mortality, requires a three-
dimensional approach: primary, secondary, and tertiary prevention [4, 6, 11, 20].
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Factors increasing the risk Relative risk
Family history and genetics
One first-degree relative 2.2
More than one relative 4.0
Relative diagnosed before 45 3.9
Individual history
Crohn’s disease 2.6
Ulcerative colitis
Colon
Rectum
2.8
1.9
Diabetes 1.2
Behavioral risk factors
Excessive alcohol
consumption
1.6
Obesity 1,.2
Red meat consumption 1.2
Processed meat consumption 1.2
Smoking cigarette 1.2
Risk reducing factors
Physical activity (colon) 0.7
Consumption of dairy products 0.8
Fruit consumption 0.9
Vegetable consumption 0.9
Total dietary fiber consumption
(10 g/day)
0.9
Table 1. Colorectal cancer risk factors and relative risk.
2.1.2.1. Primary prevention strategies
Primary prevention includes reducing the effects of carcinogens by using chemopreventive
agents or removing environmental carcinogens. The goal of primary prevention is to prevent
cancer from starting by reducing individual risk. Primary prevention focuses on lifestyle
changes and risk factors related to chemoprevention. Primary prevention measures focus on
two areas: making lifestyle changes toward changing primary risk factors and chemopreven‐
tion (chemical protection) strategies [20, 21].
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2.1.2.1.1. Lifestyle changes
Healthy body weight: Being overweight obesity increases the risk of CRC, independent of
physical activity. It is noted that abdominal obesity as measured by waist diameter is a more
important risk factor than general obesity for both women and men [8, 10]. Patient education
about ways to gain and maintain a healthy body weight is an important health professional
task. Most people know its importance but there is a need for the encouragement and support
of health professionals to implement effective interventions for individuals. Excess body fat
can be reduced by reducing caloric intake and increasing physical activity. Reducing daily
calorie intake by 50–100 calories can prevent gradual weight gain in adults, 500 calories/day
or more weight loss program is the first joint reduction target. Research has shown that up to
60 minutes a day of moderate to vigorous physical activity may be necessary to prevent weight
gain. For overweight people, daily physical activity up to 90 minutes of moderate intensity
can help in losing weight [21].
Healthy nutrition and diet: Positive dietary factors that reduce the risk of cancer include low-
fat diet (less than 24% of dietary fat content), high in fiber, high in omega 3, high fruits and
vegetables, citrus fruits, cruciferous vegetables, carotene and lycopene-rich foods, plant-based
diet, calcium, selenium, vitamin D, folic acid, omega 3 nutritional factors, and fatty acids.
Dietary factors that increase the risk of cancer include animal fat, saturated fat, red meat, burnt/
charred meat, trans fatty acids, and excessive alcohol consumption. Animal fats and con‐
sumption of excessive red meat and processed meat products increase the risk of high-calorie
diet and consumptionless fiber-rich foods [2, 6, 8, 15, 16]. An oil-poor fiber-rich diet, 20–35 g
of fiber daily for adults, and reducing total daily calories from fat by about 30%, with limited
consumption of red meat is said to help reduce the risk of CRC. Also, regular consumption of
fruits, vegetables, and calcium are recommended to reduce the risk for CRC for women and
men. Nutritional advice for cancer prevention includes plant-derived diet containing at least
five servings of fruits and vegetables every day, choosing whole grains instead of refined
carbohydrates, eating saturated fat, and restricting alcohol and excessive calorie intake [11, 17,
19, 21].
Physical activity: Physical inactivity is one of the behavioral risk factors most often associated
with CRC. Risk of CRC is lower for physically active people. Risk of CRC for very physically
active people is 25% lower than in most physically inactive people [10]. Being physically active
during both work and leisure time also reduces the risk. The American Cancer Society
recommends a minimum of 150 minutes of moderate intensity every week, and preferably
spread over the week, or 75 minutes of vigorous physical activity (or combination thereof) [10].
Avoidance of tobacco and alcohol: Smoking is more related to lung cancer but it also has quite
harmful effects on the colon and rectum. Cigarette smoking increases the risk of colorectal
adenoma [2, 6, 10, 17] and long-term use is associated with large polyps in the colon/rectum.
The numbers of polyps have been reported to increase in patients even after they quit smoking
10 years previously [8, 17]. It is stated that the relative risk of CRC development is 1.64 in
current smokers relative to nonsmokers [2], and 12% of all CRC deaths are related to tobacco
use [8, 17]. Age of smoking initiation, duration of smoking, and the amount of cigarettes
consumed per day increase the risk of CRC [18]. The difference in life risk of developing CRC
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in individuals who consume —two to four alcoholic beverages per day is greater than 23%
compared with those who consume less than one alcoholic beverage per day. Alcohol
consumption as a factor that plays a role in CRC is seen at an earlier age. The relative risk is
1.08 for alcohol intake of 25 g/day. Smoking together with alcohol consumption doubles the
risk of CRC [10, 17, 19].
2.1.2.1.2. Chemopreventive measures
The administration of drugs or natural compounds to prevent the development of CRC is
called chemoprevention. Colorectal cancer chemoprevention can be considered for advanced
adenomas greater than 1 cm with villous histology, and more than two adenomas independent
of the size of the adenoma and histology. Also, patients with a family history of cancer or cancer
in first-degree relatives benefit from chemoprevention. Some 10% of all CRC groups can benefit
from chemoprevention [22]. Research into chemoprevention of CRC is very active and
chemical measures are recommended to more people in the high-risk group [6, 18, 21, 22].
Results of studies on chemical measures vary. Nonsteroidal anti-inflammatory drugs
(NSAIDs) and aspirin have been determined to inhibit the enzyme cyclo-oxygenase (COX-1
and COX-2), which is involved in development of CRC. Regular aspirin or other NSAID use
in humans reduces CRC development by 30–50%. In the recent past, these agents were not
recommended for the general population (average risk), but today aspirin and other NSAIDs
are recommended for the average-risk group. However, aspirin and other NSAIDs have
adverse effects such as gastrointestinal bleeding and stroke, thus the benefit/risk balance of
these drugs has restricted their use. In addition, calcium, vitamin D, folic acid, hormone
replacement therapy, and the protection provided by statins need to be evaluated in further
studies [6, 18, 21, 22].
2.1.2.2. Secondary prevention strategies
Secondary prevention, which enables slow-growing lesions to be diagnosed at early stages,
includes early diagnosis and screening methods. Screening achieves better results because it
avoids the onset of new cases and enables treatment of tumors at an early stage, which provides
a better prognosis. Screening methods such as colonoscopy can identify abnormal cancerous
changes so cancer can be prevented from fully developing. Secondary prevention is often
associated with the removal of precancerous lesions or intraepithelial neoplasia (e.g., ductal
carcinoma in situ, adenoma, or hyperplasia). In this way, disease is caught at an early stage,
and the incidence of patients with advanced stage disease and mortality decreases [20, 23].
Polyps, especially adenomatous-type polyps, are known to be the precursor of CRC. The
estimated 5-year survival rate of localized tumor (limited to the bowel wall) is 90%, it is 68%
when the regional lymph node is involved, and 10% in the presence of distant metastases. CRC
screening is recommended for the entire population; some people have a higher risk of
developing CRC than others. The most important step is to assess the correct risk of developing
CRC, screening is most effective test for individuals [6, 21, 23–27].
Colorectal cancer screening tests are divided into two groups:
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• Stool tests: guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test, stool
DNA test.
• Structural analysis: flexible sigmoidoscopy (FS), colonoscopy, double barium contrast
radiography, computed tomographic (CT) colonography, virtual colonoscopy, capsule
endoscopy.
Each test has different advantages and disadvantages and can be used alone or in combination
according to the request and the status of the individual [6]. Secondary prevention measures
“Who should be screened and how?” The answer to the questions of who and which test brings
clarity to the issue of how and how much will be applied at intervals, which is why CRC
screening recommendations/guidelines have been established in many countries [6, 11, 21].
2.1.2.3. Clinical guidelines on colorectal cancer prevention
The aim of screening is to detect a precancer condition in the healthy population, as well as
very early-stage malignancies that can be treated with a clearly curative intervention. In this
context, international clinical guidelines have been created by the following organizations:
• American Cancer Society (ACS), The US Multi-Society Task Force on Colorectal Cancer
(USMSTF), and American College of Radiology
• U.S. Preventive Services Task Force (USPSTF)
• National Comprehensive Cancer Network (NCCN)
• European Society for Medical Oncology (ESMO)
Screening tests and follow-up intervals are implemented and updated frequently by these
organizations, depending on study results and technical improvements. The recommenda‐
tions are not applied in the same way for the whole population; there are variations between
countries and appropriate tests are recommended based on individual risk situations [6, 11,
16, 21, 24–28]. Although all guidelines recommend starting routine screening for CRC and
adenomatous polyps in asymptomatic adults at age 50, there is less agreement as to the
screening method, frequency of screening, and at which age screening may be safely discon‐
tinued. The recommendations differ for the method, frequency, and age of screening com‐
mencement in high-risk patients.
American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and
American College of Radiology (ACR) guidelines were published in 2008 [6, 21, 24]. These
guidelines recommend starting screening in asymptomatic men and women at age 50 years.
Any test that can detect adenomatous polyps can be used for screening adults at average risk.
Table 2 lists the tests and their recommended frequency of use. Individuals with family history
of CRC, polyps, or one of the hereditary CRC syndromes, or a personal history of CRC or
chronic inflammatory bowel disease are recommended to undergo colonoscopy at younger
ages and more frequently than individuals at average risk (Tables 3 and 4) [24, 28].
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Test Interval recommendations Training issues to facilitate decision-making advantage/disadvantage
Flexible
sigmoidoscopy
Every 5 years1,2
Every 10 years3
The optimal interval should
not be <10 years and may
even be extended to 20 years3
• Full or partial bowel preparation is required
• Sedation is not generally used, so there may be
some difficulties during the process
• The protective effect is limited to the examined
column section
• If results are positive, people are generally directed
to colonoscopy
• Low risk of bleeding, infection, and perforation
Colonoscopy Every 10 years1,2,3
The optimal interval should
not be <10 years and may
even be extended up to 20
years3
• Full bowel preparation is required
• Awareness under sedation used in most centers
• A business day may be needed for resting
before the preparation and after the process
• Transportation (car cannot be used after sedation)
and travel companion is required
• Biopsy can be taken during the procedure, polyps can
be removed
• Rare but potentially serious risk of perforation and
hemorrhage; risk increases with polypectomy
Double-contrast
colonography
Every 5 years1,2
Uncertain3
• Full bowel preparation is required
• The biopsy cannot be done during the procedure
• If one or more polyps >6 mm, colonoscopy will be
recommended; follow-up colonoscopy will require full bowel
preparation
• Sedation is generally not used, so there may be some
difficulties during the process
• Low-risk, rare perforations have been reported
Virtual
colonoscopy/
CT colonography
Every 5 years1
Uncertain2,3
• Full bowel preparation is required
• If one or more polyps > 6 mm, colonoscopy will be
recommended; if colonoscopy is not possible on the same day, full
bowel
preparation is needed before the colonoscopy
• Sedation is not used, so there may be some difficulties
during the process
Colorectal Cancer Prevention and Risk Counseling
http://dx.doi.org/10.5772/63206
127
Test Interval recommendations Training issues to facilitate decision-making advantage/disadvantage
• Low-risk, rare perforations have been reported
• Extracolonic abnormalities can be identified and require
further evaluation
1American Cancer Society, USMSTF, American College of Radiology screening guide.
2National Comprehensive Cancer Network (NCCN).
3ESMO guidelines and European guidelines for quality assurance in colorectal cancer screening and diagnosis [6, 13,
21, 24–27].
Table 2. Average risk for colorectal cancer, tips for individuals in the group, follow-up frequency, and advantages and
disadvantages.
Test Recommendations
interval
Training issues to facilitate decision-making advantage/disadvantage
Guiac-based
FOBT
Annually1, 2
Annually3
The test interval
should not
exceed 2 years3
• Depending on the manufacturer’s recommendation, 2–3
stool samples collected at home are required to complete the test;
stool sample collected during a single examination at the clinic,
touching stool test is not acceptable and should not be used
• No risk of perforation of the intestine
• Can be done at home, increase the protection of privacy
• It is relatively cheap compared with other tests
• If results are positive, further evaluation with colonoscopy
is needed
• Avoid consumption aspirin, NSAIDs, vitamin C, red meat,
poultry, fish, and raw vegetables for 48 hours before the test
Fecal immuno-
chemical test
Annually1
Uncertain2
The test interval
should not exceed 3 years3
• If results are positive, further evaluation with colonoscopy
I needed
• Single tests are often ineffective
• The transportation of the material to the laboratory requires
specific instructions and appropriate protective material
• No risk of perforation
• Protection of privacy as can be done at home
Stool DNA test Uncertain1,2,3 • A test sample should be sufficient and should be packaged
in suitable preservative for transportation to the laboratory
• More expensive than other stool tests
• If the test result is positive, further evaluation with colonoscopy
is needed. If the test is negative, it is not clear, the test should be
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Test Recommendations
interval
Training issues to facilitate decision-making advantage/disadvantage
repeated at appropriate intervals
• No dietary restrictions
• Protection of privacy increased as can be done at home
• No risk of perforation
1American Cancer Society, USMSTF, American College of Radiology screening guide.
2National Comprehensive Cancer Network (NCCN).
3ESMO guidelines and European guidelines for quality assurance in colorectal cancer screening and diagnosis [6, 13,
21, 24–27].
Table 2. Moderate risk for colorectal cancer, tips for individuals in the group, follow-up frequency, advantages and
disadvantages (continued).
Risk category Starting year Recommendations/interval Comment
CRC or adenomatous
polyps in the first 60
years of first-degree
relative or two or more
first-degree relatives at any
age
40 years, or 10 years younger
than the age of the CRC
diagnosis in the youngest
relative CRC diagnosis1,2
40 years, or 5 years younger
than the age of cancer onset in
first-degree relatives3
Colonoscopy1,2
FOBT and colonoscopy3
Every 5 years1,2,3
Two adenomatous/CRC
polyps in first- or second-
degree relatives aged over
60 years
40 years1,2 or 5 years younger
than the age of disease onset in
first-degree relatives3
Screening frequency and
recommendations for moderate
risk individuals are applied1,2
Screening/follow-up procedure
will be determined by clinical
follow-up of patients3
Individuals can
now scan any
screening test but
should begin at
an early age
1American Cancer Society, USMSTF, American College of Radiology screening guide.
2National Comprehensive Cancer Network (NCCN).
3ESMO guidelines and European guidelines for quality assurance in colorectal cancer screening and diagnosis [6, 13,
21, 24–27].
Table 3. Recommendations and colorectal cancer screening tests for individuals in the increased-risk group.
Risk category Starting year Recommendations/interval Comment
Genetically
diagnosed with
FAP or without
evidence of
10 or 12 years old1,2
Starting at age 12–14 years
and continued lifelong in
mutation carriers3
Individual genetic anomaly
that carries genetic tests to
determine the annual FSA and
consulting requirements1,2
Sigmoidoscopy every 2 years3
If genetic testing is positive,
colectomy should be considered
Screening and monitoring
procedures following clinical cases
will be determined3
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Risk category Starting year Recommendations/interval Comment
genetic testing and
those suspected in
FAP
Once adenomas are detected, annual
colonoscopy should be carried out
until colectomy is planned3
For AFAP Starting at age 18–20 years
and continued lifelong in
mutation carriers. 3
Colonoscopy every 2 years3 After adenomas are detected,
colonoscopy should be carried out
annually3
Genetically or
clinically
diagnosed with
HNPCC
individuals, or
high-risk
individuals for
HNPCC
20–25 years of age or
their immediate family
members or 10 years
younger than
the age of the CRC diagnosis
in the
youngest relative1,2
Starting at age 20–25 or
5 years before the
youngest case in the family3
Colonoscopy every 1–2 years
and counseling on whether the
genetic testing is
necessary1,2Colonoscopy every
1–2 years.3 Upper limit is
not established.3
First-degree relatives of people with
known hereditary MMR gene
mutations should be offered genetic
testing for HNPCC. Family mutation
as yet unknown, but also those
having one of the first three criteria
of modified Bethesda should be
recommended
Screening and monitoring
procedures following clinical cases
will be determined3
1American Cancer Society, USMSTF, American College of Radiology screening guide.
2National Comprehensive Cancer Network (NCCN).
3ESMO guidelines and European guidelines for quality assurance in colorectal cancer screening and diagnosis [6, 13,
21, 24–27].
Table 4. Recommendations and colorectal cancer screening tests for individuals in the high-risk group.
US Preventive Services Task Force (USPSTF):
The US Preventive Services Task Force (USPSTF) recommends using high-sensitivity fecal
occult blood testing, sigmoidoscopy, or colonoscopy from the age 50 years and to continue
until the age of 75 years [28]. Higher risk individuals should begin screening at a younger age,
and likely more frequently. Whether individuals need to be screened beyond the age of 75
years must be decided on an individual basis. Recommended screening tests and intervals are
as follows:
• High-sensitivity fecal occult blood test (FOBT)—annual
• Flexible sigmoidoscopy—5 yearly (every 3 years with FOBT)
• Colonoscopy—every 10 years
Colonoscopy can be used for screening or as a follow-up diagnostic tool in symptomatic
patients, or when the results of another CRC screening test are unclear or abnormal [28].
The National Comprehensive Cancer Network (NCCN):
The National Comprehensive Cancer Network (NCCN) has released separate guidelines for
average- (Table 2), increased- (Table 3), and high-risk individuals (Table 4). For average
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individuals, the NNCN’s guidance is almost identical to that of the ACS, USMSTF, and ACR.
These guidelines make recommendations for each risk factor for individuals at high risk [27,
28].
European Society for Medical Oncology (ESMO):
According to all international guidelines, screening tests are stratified according to the
personal risk of disease. The CRC screening guidelines of ESMO are in parallel with the guiding
principles of the European guidelines. The ESMO recommendations for average-, increased-,
and high-risk individuals are shown in Tables 2–4, respectively. Guaiac (g) FOBT reduced
CRC mortality in average-risk populations by 15% in different age groups. To date, only FOBT
has been recommended for men and women aged 50–74 years. Fecal immunochemical testing
appears to be superior to gFOBT with respect to detection rates and positive predictive values
for adenomas and cancer. Flexible sigmoidoscopy has been demonstrated to reduce CRC and
mortality rates when conducted in organized screening programs. FS screening should be
discontinued in patients of average risk aged more than 74 years because of the increased
number of comorbidities in this population. There is no current evidence to support adding
in a one-off sigmoidoscopy to FOBT screening. There is limited efficacy of colonoscopy in
reducing CRC incidence and mortality. The optimal age for a single colonoscopy is circa 55
years but the age range for this test is 50–74 years. Newer screening techniques such as
computed tomography colonography, stool DNA testing, and capsule endoscopy are still
under evaluation and as such should not yet be relied upon to screen the average-risk
population [29, 30].
Colorectal cancer screening remains a subject of debate regarding to whom, with which
method, and at what frequency; however, its cost-effectiveness has been demonstrated and
this is key in influencing the decision to implement CRC screening programs [7, 31]. Policy‐
makers and health professionals who decide on which CRC screening strategy to recommend
or implement must be well informed. It is vital that resources are used efficiently when
planning or implementing nationwide CRC screening programs, and that a cost-effective
option for CRC screening is selected. According to the results of recent review studies, there
is a complexity which screening test is the most cost-effective and which screening test should
be chosen [7, 31].
Individuals are divided into categories according to their risk of CRC, and the type and
frequency of screening methods varies depending on the risk category [6, 21, 23–27]. The risk
of developing CRC for an individual is classified into three categories: moderate risk, increased
risk, and high risk; screening is recommended in accordance with the risk group of individuals
[6, 13]. Persons with known gene mutation or those with suspected gene mutations have a
very high risk of contracting the disease [6, 13, 21, 24–27].
2.1.2.3.1. Moderate/average-risk group
Everyone is under the lowest risk for CRC [21]. Personal and family history of colorectal polyps
or ulcerative colitis without CRC, chronic inflammatory bowel disease such as Crohn’s disease
without CRC, and all individuals aged 50 years and over are at average risk [6, 21, 24–27].
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Individuals at average risk are recommended for screening; the frequency of follow-up is
shown in Table 2.
2.1.2.3.2. Increased risk group
In this group, risk of CRC is growing twice according to the individuals in average risk.
Individuals with a history of adenomatous polyps are at significantly higher risk. A family
history of CRC or adenoma increases a person’s risk of developing CRC. If there is a family
history CRC or adenomas including first-degree relatives (mother, father, sibling, or child)
before the age of 60, the risk of developing CRC at any age (—three to four times the average
risk) significantly increases. Screening recommendations for high-risk individuals are shown
in Table 3.
2.1.2.3.3. High-risk group
The risk of CRC in individuals with a known genetic mutation is high. The most common
hereditary CRC syndrome, HNPCC, also known as Lynch syndrome, is an autosomal
dominant syndrome and accounts for 3–5% of all CRCs. Familial adenomatous polyposis,
which is characterized by multiple adenomatous colonic polyps, is an autosomal dominant
syndrome comprising 1% of all CRC cases. For the FAP, the average age of cancer diagnosed
is 39 years for FAP, but in the individuals with FAP 75% of adenomas occurred in 20 years.
Recommended screening and surveillance programs for high-risk individuals are shown in
Table 4 [6, 21, 24, 30].
2.1.2.4. Tertiary prevention strategies
Tertiary prevention is used in the treatment of specified diseases or prevention of complica‐
tions associated with the disease, is often used to treat one type of cancer and metastasis, or
involves treating patients at risk for development of a secondary primary cancer [20]. The
target of tertiary prevention in cancer patients is to reduce morbidity and mortality with the
optimal treatment. Primary and secondary prevention practices are recommended in devel‐
oping or less developed countries due to the fact that greater economic burden of tertiary
prevention [20].
2.2. Colon cancer risk counseling
Today, although advances in treatment and screening standards established successful tests
for CRC, it is not perceived as a curable and preventable disease. Many people do not know
that even simple measures can prevent CRC. Cancer can be prevented in some individual cases,
and it is very important to develop the perception in the community and belief that cancer can
be prevented and is curable. Determining the level of risk and interpretation, encouraging
preventive behaviors, and improving the early diagnosis and screening behaviors are impor‐
tant parts of early detection and screening programs. Prevention of colon cancer will be
successful with the health efforts of professionals to increase awareness of the disease, risk
assessments, counseling programs with appropriate recommendations, and diagnose the
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patients in an early stage [32, 33]. In studies conducted in recent years in the prevention of
cancer, “cancer risk counseling” concept stands out [32, 34]. Physicians and nurses who work
in primary healthcare services and oncology units have an important role and responsibilities
in implementing programs and changing behavior that encourages early screening and
diagnosis of cancer. Cancer risk counseling focuses on genetic assessment, assessment of
individual risk factors, and the development of a risk management plan [35]. At this point,
health professionals trained in CRC counseling can take control of their risk by reaching the
individuals at an early stage [11, 12, 32, 36, 37]. Cancer risk counseling should be done in a
second step in primary care with asymptomatic individuals at moderate risk and members of
the increased-risk and high-risk groups. For example, risk counseling to individuals who have
registered in family medicine and family health centers in the moderate-risk group is given
by public health nurses. Family of individuals with hereditary CRC and of patients are
counseled by doctors and nurses in clinical oncology for as long as treatment continues, or by
clinical staff of family cancer clinics/genetic private surveillance programs or outpatient clinics,
for those with chronic bowel disease if they are under follow-up [32, 36–38]. To conduct CRC
risk counseling, physicians and nurses must have the authority and knowledge on this subject.
This risk counseling process encompasses a comprehensive cancer risk assessment, and
determining genetic predisposition, information, guidance training and screening, genetic
counseling, and creation of a risk management plan that includes the monitoring and evalu‐
ation plan. To achieve effective results in risk counseling, giving individual-specific messages,
making an assessment of risk status together with the individual, and supporting the individ‐
ual in the decision-making process is essential. In addition, it is aimed to follow-up screening
participation of the individuals, and guide individuals who receive abnormal test results. Thus,
CRC risk counseling aims to reduce morbidity and mortality with an increase in screening
rates and to detect disease at an early stage [33, 35, 38].
Risk advisor staff who conduct risk counseling and risk assessments must have certain
characteristics. CRC staff have to have adequate current information about hardware, com‐
munication techniques, good training, and counseling skills. Also, a counseling room should
have adequate ventilation and lighting systems suitable for training and counseling. Colorectal
cancer risk counseling identifies risk factors for an individual that can and cannot be changed
(hazard identification/risk assessment); screening for risk factors proposition includes
monitoring of behavior change initiatives and behavioral changes [38].
2.2.1. Stages of colorectal cancer risk counseling
Colorectal cancer risk counseling includes individual education and counseling and is
implemented in three stages [32, 38]:
Stage 1: Application phase
Stage 2: Follow-up phase
Stage 3: Evaluation phase
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2.2.1.1. Application phase
The creation of awareness through risk assessment and transfer of disease-specific informa‐
tion/education consist of three parts. Before making giving detailed information, disease
awareness should be created for the individual, the individual’s attention should be directed
toward the subject and they should be allowed to ask questions [38]. At this stage, awareness
about factors that increase the risk of disease must be created, and behavioral changes must
be implemented in order to ensure appropriate counseling skills and evidence-based inter‐
ventions [14]. A wide range of communication media have been used in studies aiming to
increase awareness of CRC screening ranging from personal letters to TV advertisements.
While facilitating effective participation in CRC screening initiatives, such as reminders, mass
media and the media, group training, personal training, and assessments, are taken by
reducing structural barriers to healthcare professionals and include initiatives such as
feedback. The effectiveness of personal reminders, personal training, and counseling in
improving CRC screening has been proven [10, 25, 39–44].
Sections Initiatives/methods Tools
Application phase
Creating
awareness
Initiative: CRC risk factors, prevention, information
about early diagnosis
Method: Face-to-face interviews, telephone interviews,
video/slide show, introduce role models, motivational
interviewing, send letters
Banners, posters, models, TV and
newspaper advertisements, letters, mail/
invitation via e-mail, phone messages,
calendars, giveaway/inducers such as
promotion, promotional stands
Risk assessment Initiative: Determine the risk rating of the individual
Method: Face-to-face interviews, computer-aided risk
assessment models
Risk assessment tables, pedigree charts,
graphs, histograms, electronic health records
Disease-specific
information
Initiative: Provide adequate and appropriate
information about the disease
Method: Face to face interviews
Slides, posters, pamphlets, educational
videos, health beliefs scales, written
materials
Follow-up phase
Initiative: Maintain awareness, support positive
behavior, follow-up/surveillance of screening behavior
Method: Interview
Phone calls, text messages, e-mail,
reminders, call center awards
Evaluation phase
Initiative: Preventive screening behavior and
participation in evaluation, assessment test results
Method: Face-to-face interviews
Automated phone calls
Web-based assessment
Table 5. Colorectal cancer risk counseling can be applied in all stages of evidence-based initiatives.
Creating awareness: Various implications may be used in order to create awareness in the
individuals about the importance of their protective behaviors in the prevention of CRC and
their health. Evidence-based interventions recommended in the recent relevant studies are
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shown in Table 5 [10, 25, 39–44]. Due to purpose of encouraging individuals take action to
protective behaviors, it is important to give positive messages in materials (e.g., posters,
banners) that it is possible to protect against CRC [11, 36, 37]. Risk assessment is required for
each individual in order to determine the screening interval and proper test [21, 33].
Risk assessment: It is important to be able to receive adequate health history. The scope of
individual members in the counseling process assessment includes the following:
• demographic, socioeconomic, cultural characteristics, and medical history (previous/
existing diseases, especially chronic bowel disease, polyps),
• a detailed family history (especially first- and second-degree relatives),
• cognitive and psychosocial (cognitive capacity, CRC knowledge, risk perception, CRC-
related health beliefs and attitudes, perceptions, motivation, concerns, barriers, CRC
relevant experience, anxiety and fears, coping mechanisms and social support status,
decision-making and decision support systems),
• lifestyle behaviors (habits that increase the risk of CRC, dietary behaviors, physical activity
status, smoking and alcohol use, stress level, given the importance of such a negative
attitude and a healthy lifestyle),
• do not collect data on exposure to environmental risk factors and other characteristics.
Risk assessment tools for practical risk assessment (risk calculation tool, pedigram) can be
made using electronic health records [10, 25, 33, 35, 39, 45]. According to the data obtained, a
risk rating of the risk assessment is performed. The risk rating is how to determine whether
an individual is at risk and making orientation relative to the risk. The degree of risk of cancer
is important in guiding the individual screening tests [6, 11, 21]. In this regard, national/
international guidelines should be considered. Risk assessment, web-based tools, and mathe‐
matical models of interpretation of risk may make it easier to use directed individual protection
proposals. Graphical presentation of risk status (bar, pie, histogram) makes it easier to explain
and to understand the risk [6, 21, 33, 45]. Health behavior models have been developed for
people to understand why there are different health behaviors or practices they are going to
implement. While counseling individuals, health behavior models act as a “black box” to
determine factors that affect preventive behaviors and to change negative behaviors to
positive. These models are Health Belief Model, Transtheoretic Model, Health Promotion, and
Preventive Health Model [11, 12, 14, 38, 39].
The risk status of the individual is described in a way that can be understood. Words, tone of
voice, body images, and facial expressions of health personnel can affect the understanding
individual risk information. The level of education of the individual, age, cultural, and
linguistic differences should be taken into account. In addition, the cost of diagnosis and
treatment, transportation requirements, communication, and cultural characteristics are
important for the care of the patient’s decision. Particular circumstances of the individual (e.g.,
affected my social and personal values, and economic and environmental conditions) should
be considered. Individuals are given information regarding their assessment and risk diag‐
nostics; when interpreting cancer risks, results that will disrupt the motivation for the indi‐
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vidual’s protection behavior or descriptions that will cause anxiety/fear should be avoided [33,
45].
Sufficient disease-specific information: The aim is to address the lack of knowledge about the
disease and the individual CRC screening tests (fecal occult blood test, colonoscopy, double-
contrast bowel X-ray, sigmoidoscopy). Patients training sessions should include information
on colon and rectal anatomy of the digestive system, CRC generation, CRC signs and symp‐
toms, risk factors, the importance of disease prevention, prevention, healthy lifestyle behav‐
iors, early diagnosis and screening tests, the advantages and disadvantages of each test, and
information about CRC protection behavior information [11, 21, 32, 35, 38, 39, 45]. Taking
appropriate initiatives to scan an individual’s risk rating should be provided and monitored
(see Table 5). Encouragement of positive behavior aimed at reducing CRC risk and altering
health beliefs associated with the disease are very important. Therefore, the individual’s health
beliefs during counseling, motivation, and barriers to education in this direction may be
determined by a variety of scales [11, 21, 38]. Video display and printed materials in the
education department, presentations, and motivational interviewing techniques such as active
listening are available. There are no studies on the use of individual incentives that promote
screening (a small amount of money, coupons, gift certificates); therefore, there is insufficient
evidence to support this initiative alone. After the training, short appropriate tests should be
conducted in order to evaluate the effectiveness of the training; individuals who then wish to
undergo screening should be referred to the relevant departments and clinics [38].
2.2.1.2. Follow-up phase
Maintainance of awareness of the individual is intended to support the CRC protection
behavior. It will increase the importance of the disease and practical initiatives to ensure the
consistency of behavior covered in the training. The next follow-up face-to-face meeting in the
implementation phase can be done through methods such as e-mail or telephone (Table 5).
During these initiatives, any information that was given during training that was not clear can
be questioned. For example, healthy lifestyle behaviors and screening recommendations for
prevention of CRC can be repeated/reviewed, and information can be discussed about where
to go in the event of receiving negative test results. At this stage, the behavior of individuals
regarding disease protection is expected to show increased enthusiasm. All associated
individuals (family, friends, healthcare professionals) are encouraged to support positive and
protective behavior [11, 12, 21, 25, 35, 38].
2.2.1.3. Evaluation phase
At this stage, CRC protection behavior exhibited by the individual is evaluated. Changing an
individual’s behavior is not a goal that can be realized in a short time, it requires long-term
follow-up. In order to ensure continuity, to maintain positive behaviors and enable behavior
changes to occur, regular implementation of risk counseling (e.g., 3, 6, 12, 24 months) should
be carried out [34, 35, 39]. The evaluation phase, which allows for obtaining feedback from
individuals, is usually advised to be face to face. Reasons for an individual wishing to end the
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program should be taken to identify obstacles and need to reschedule procedures overcome
these barriers [11, 12, 21, 32, 35, 38, 41, 45].
3. Conclusions
Primary and secondary prevention practices in the management of CRC are to be carried out
together. Applying primary measures alone will not be enough, only having screening tests
will not prevent the disease occurrence. Primary healthcare physicians and nurses have an
important role in the implementation of risk counseling. Colorectal cancer risk counsellers are
required to have special knowledge and skills. Therefore, the staff who undertake counseling
are required to have received appropriate training. Colorectal cancer risk counseling is a
process that applies to all stages of implementation, including monitoring, evaluation stages,
and health services. Many initiatives and recommended methods for each stage of the process
have been demonstrated in research. Adequate training in CRC risk counseling practice of
health professionals, all relevant employees in surgery, oncology, and public health has been
estimated to reduce the incidence of CRC.
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